Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15153756 | 0.84 | LMNA (0.37) | — | |
| SCHEMBL2526072 | 0.76 | GPR119 (0.44) | — | |
| SCHEMBL2518419 | 0.74 | STK17B (0.46) | CA1CA2CA12CA9BRD4 | |
| SCHEMBL2524679 | 0.74 | DRD2 (0.47) | DRD2SIGMAR1TDP1CNR2 | |
| SCHEMBL2520726 | 0.74 | KAT2B (0.32) | STK17A | |
| SCHEMBL2522598 | 0.73 | LMNA (0.41) | — | |
| SCHEMBL12210118 | 0.73 | GPR119 (0.42) | — | |
| SCHEMBL14800382 | 0.73 | DRD2 (0.48) | DRD2SIGMAR1 | |
| SCHEMBL25407920 | 0.72 | TDP1 (0.45) | DRD2CA1CA2CA12CA9 | |
| SCHEMBL2518726 | 0.72 | TDP1 (0.40) | DRD2CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | DRD2 4827/4885CA1 3447/4885CA2 1868/4885 |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | DRD2 4827/4885CA1 3447/4885CA2 1868/4885 |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | DRD2 4827/4885CA1 3447/4885CA2 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.